Title : Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Pub. Date : 2008 Dec 15

PMID : 18772452






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Lenalidomide keratin 20 Homo sapiens
2 The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide. Lenalidomide keratin 20 Homo sapiens
3 In contrast to previous reports using CD20-positive lymphoma cell lines, lenalidomide down-regulated CD20 surface antigen expression in CLL patient cells via enhanced internalization, without influencing transcription. Lenalidomide keratin 20 Homo sapiens
4 In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC. Lenalidomide keratin 20 Homo sapiens
5 In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies. Lenalidomide keratin 20 Homo sapiens